Last reviewed · How we verify
Ringerfundin
Ringerfundin is a Small molecule drug developed by University Hospital Olomouc. It is currently in Phase 3 development. Also known as: Ringerfundin (B. Braun).
Ringerfundin is a balanced crystalloid solution used for volume therapy, as indicated by its use in a clinical trial comparing it to gelatine solution for treating various conditions such as hemorrhage, surgical complications, and hip replacement surgery. It is manufactured by B. Braun and was studied alongside Gelofusine, a gelatine solution, in a clinical trial at the Brno University Hospital.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ringerfundin |
|---|---|
| Also known as | Ringerfundin (B. Braun) |
| Sponsor | University Hospital Olomouc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Perioperative Fluid Therapy Optimization in Spinal Surgery (NA)
- Perioperative Fluid Therapy With Balanced Crystalloids (PHASE3)
- Comparison of the Effects of Gelatine Versus Balanced Crystalloid Solution for Volume Therapy (NA)
- Scandinavian Starch for Severe Sepsis/Septic Shock Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ringerfundin CI brief — competitive landscape report
- Ringerfundin updates RSS · CI watch RSS
- University Hospital Olomouc portfolio CI
Frequently asked questions about Ringerfundin
What is Ringerfundin?
Who makes Ringerfundin?
Is Ringerfundin also known as anything else?
What development phase is Ringerfundin in?
Related
- Manufacturer: University Hospital Olomouc — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Ringerfundin (B. Braun)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing